Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The Hub & Spoke model is designed to extend advanced medical care to a wider community
The platform is being introduced to expand access to treatments for people living with chronic conditions
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Subscribe To Our Newsletter & Stay Updated